According to AIS Health’s RADAR on Medicare Advantage publication, 74 Medicare Advantage Prescription Drug Plan (MA-PD) contracts earned a 5-star rating for 2022, compared with just 21 such plans last year. In “Potential 5-Star SEP Disruption Depends on Marketing Prowess,” Faegre Drinker Consulting Principal Mike Adelberg commented on how these MA-PD plans might market 5-star products.
“The past is not necessarily prologue regarding the 5-star Special Enrollment Period (SEP),” observed Adelberg. “With more national plans achieving 5-stars this year, their year-round marketing might not resemble what we’ve seen from the year-over-year 5-star provider-owned plans.”
The full article is available for RADAR on Medicare Advantage subscribers.